MARKET

SLNO

SLNO

Soleno Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2199
+0.0256
+13.18%
Opening 12:20 07/07 EDT
OPEN
0.2000
PREV CLOSE
0.1943
HIGH
0.2200
LOW
0.1999
VOLUME
1.46M
TURNOVER
205.29K
52 WEEK HIGH
1.070
52 WEEK LOW
0.1302
MARKET CAP
26.41M
P/E (TTM)
-0.6341
1D
5D
1M
3M
1Y
5Y
Here's Why Assertio Holdings (ASRT) Stock is Up This Year
Assertio Holdings' (ASRT) successful execution of its restructuring plan, resulting in significant cost savings, is boosting profits.
Zacks · 2h ago
Zacks Industry Outlook Highlights Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics
Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics are part of Zacks Industry Outlook article.
Zacks · 3h ago
4 Small Stocks to Bet on in an Upbeat Drugs Industry
It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.
Zacks · 1d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 06/21 21:45
Mid-Day Market Update: Dow Turns Lower; Qudian Shares Surge
U.S. stocks pared gains midway through trading, with the Dow Jones and S&P 500 turning lower on Tuesday.
Benzinga · 06/14 16:12
41 Stocks Moving In Tuesday's Mid-Day Session
Gainers Revlon, Inc. (NYSE: REV) rose 125.5% to $2.6499. Revlon’s stock dropped sharply on Monday after the company is reportedly expected to file for bankruptcy.
Benzinga · 06/14 16:07
Why Soleno Therapeutics Shares Are Surging Today
Benzinga · 06/14 09:56
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 48.5% to $2.57 in pre-market trading after the company reached an agreement with Phillip Morris for international electronic nicotine delivery system product distribution.
Benzinga · 06/14 09:54
More
No Data
Learn about the latest financial forecast of SLNO. Analyze the recent business situations of Soleno Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SLNO stock price target is 5.00 with a high estimate of 7.00 and a low estimate of 3.000.
High7.00
Average5.00
Low3.000
Current 0.2199
EPS
Actual
Estimate
-0.11-0.08-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 57
Institutional Holdings: 50.93M
% Owned: 42.41%
Shares Outstanding: 120.09M
TypeInstitutionsShares
Increased
10
12.77M
New
7
10.03M
Decreased
13
836.31K
Sold Out
5
131.15K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.73%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Non-Executive Chairman/Independent Director
Ernest Mario
President/Chief Executive Officer/Chief Operating Officer/Director
Anish Bhatnagar
Chief Financial Officer
James Mackaness
Vice President
Patricia Hirano
Vice President
Kristen Yen
Independent Director
William Harris
Independent Director
Gwen Melincoff
Independent Director
Andrew Sinclair
Independent Director
Birgitte Volck
No Data
No Data
About SLNO
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for the treatment of rare diseases. Its lead drug, Diazoxide Choline Controlled-Release tablets (DCCR), is a potent ATP-sensitive potassium (KATP) channel activator. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex diseases like Prader-Willi syndrome (PWS) to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance, and reduce body fat. It appears that many of the problematic behaviors in conditions like PWS may have hyperphagic drive as a root cause and may therefore be improved by addressing hyperphagia. The Company has a Fast-Track designation for DCCR in PWS and an orphan drug designation for the drug in the United States and European Union. Its development pipeline includes proposed diagnostic devices for asthma in children.

Webull offers kinds of Soleno Therapeutics Inc stock information, including NASDAQ:SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.